anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hemolysis can occur during treatment of methemoglobinemia with methylene blue. Laboratory testing may show Heinz bodies, elevated indirect bilirubin and low haptoglobin, but the Coombs test is negative. The onset of anemia may be delayed 1 or more days after treatment with methylene blue injection. The anemia may require red blood cell transfusions [see Adverse Reactions (6.1)]. Use the lowest effective number of doses of methylene blue injection to treat methemoglobinemia. Discontinue methylene blue and consider alternative treatments of methemoglobinemia if severe hemolysis occurs. Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with methylene blue may result in severe hemolysis and severe anemia. Methylene blue is contraindicated for use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency [see Contraindications (4)].
Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Bacterial blight (BB) caused by Xanthomonas oryzae pv. oryzae is one of the epidemic diseases in rice. Rapid changes in the pathogenicity of the X. oryzae pv. oryzae pathogen demand the identification and characterization of novel BB resistance genes. Here, we report the transfer and mapping of a new BB resistance gene from Oryza rufipogon acc. CR100098A. Inheritance studies on the BC2F2 population, BC2F3 progenies, and backcross-derived recombinant inbred lines derived from a cross between Pusa44/O. rufipogon acc. CR100098A//2*PR114 showed that a single recessive gene confers resistance in O. rufipogon acc. CR100098A. Bulked segregant analysis using 203 simple sequence repeat (SSR) markers localized the BB resistance gene on chromosome 11 bracketed between two SSR markers, RM27235 and RM2136. Using PR114 and O. rufipogon acc. CR100098A genotyping by sequencing data, 86 KASP markers within the bracketed region were designed and tested for bulked segregant analysis. Only five KASP markers showed polymorphism between parents, and three were associated with the target gene. Seventy-seven new SSR markers were designed from the same interval. A total of 33 polymorphic markers were analyzed on the whole population and mapped the BB gene in an interval of 2.8 cM flanked by SSR markers PAU11_65 and PAU11_44 within a physical distance of 376.3 kb. The BB resistance gene mapped in this study is putatively new and designated as xa49(t). Fourteen putative candidate genes were identified within the xa49(t) region having a role in biotic stress resistance. The linked markers to the xa49(t) gene were validated in other rice cultivars for its successful deployment in BB resistance breeding.
The purpose of this study is to assess feasibility of adapting an established gestational weight gain intervention approach to the specific needs of women in Arkansas. A formative phase will inform appropriate adjustments to existing intervention features as well as the support requested for wearing a continuous glucose monitor and reviewing its data. Like the original intervention, the newly adapted intervention will encourage participants to meet the updated exercise guidelines for pregnancy which recommends 30 min or more of moderate exercise a day on most if not all days of the week, and to eat a balanced diet within a caloric intake range conducive to appropriate gestational weight gain. Participants will be required to provide a daily bodyweight and step count which will be transmitted automatically with daily use of the provided devices (internet connected bodyweight scale, and pedometer). Participants in the intervention group will also wear a CGM sensor throughout pregnancy to track temporal glucose profiles. SmartMoms (trademarked) is an evidence based behavioral intervention designed to encourage appropriate gestational weight gain in women with overweight and obesity. Women will receive daily prompts and feedback on their current weight gain trajectory. Prompts will include educational sessions on healthy eating and exercising during pregnancy and will be delivered electronically to participant's smartphones and email. Participants will interact with RD health coaches and review their activity and dietary choices. The intervention group will also review their glycemic patterns in response to these choices with the study RDs. To provide participant support, the investigators will establish a closed online forum/group for community support and exchange, following the SmartMoms framework. Women will be in either SmartMoms or SmartMoms +CGM for 28 weeks, from week 12 - 40 of pregnancy. All SmartMoms counseling sessions will be conducted by a trained research staff member, and the participants will be trained on a one-to-one basis on how to engage with SmartMoms and the CGM component safely.
<P>PROBLEM TO BE SOLVED: To provide a hair dyeing method which controls hair damage to the hair having color unevenness after chemical treatment with a hair dye, a hair bleaching agent, a permanent wave agent, a hair straightener, and the like, provides the hair with sufficient gloss and uniformly dyes the hair.  <P>SOLUTION: This hair dyeing method is the one useful for chemically treated hair and is equipped with a preparation process (I) and a dyeing process (II). The preparation process (I) is a process for mixing a first agent with a second agent to prepare a slightly alkaline hair dye composition. The dyeing process (II) is a process for coating the hair with the slightly alkaline hair dye composition and allowing the hair to stand for a fixed time to carry out hair dyeing treatment. The finely alkaline hair dye composition comprises the first agent and the second agent. The first agent comprises an oxidation dye, an alkali agent and water. The second agent comprises an oxidizing agent. The first agent comprises further (A) a phosphoric acid ester-based compound, (B) a nonionic amphiphilic compound, (C) a higher fatty acid and (D) a 12-14C higher alcohol and is a gel-like composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
<P>PROBLEM TO BE SOLVED: To provide a method for producing cyclododecatriene by trimerizing butadiene in the presence of a catalytic system and a solvent by a continuous or discontinuous method.  <P>SOLUTION: The method for producing the cyclododecatriene is carried out as follows. A compound containing at least one kind of elements of main group 5 in the elemental periodic table is added to the catalytic system, and the solvent is allowed to contain 10-1,000 ppm polar component of general formula HO-R before addition of the catalytic components. The reaction temperature is ≤140°C when a nickel-containing catalytic system is used, and ≤80°C when a titanium-containing catalytic system is used. The obtained crude cyclododecatriene can be isolated by distillation, and cyclooctadiene formed as a by-product can also be isolated from the crude product.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
Pharmaceutical compsns. for oral administration comprise ascetic acid and/or one of its derivs and 14,15-dihydro eburnamenine 14-thione (vincathione), of formula (I) or its pharmaceutical acceptable salt. The ascorbic acid may be present as the free acid, a salt or a complex, pref. an equimolar complex of ascorbic acid and nicotinamide or ascorbic acid and pyridoxine, either anhydrous or monohydrated, or vincathione ascorbate. Mixtures may also be used in which the ratio vincatione: ascorbic acid by wt. are 4-1 : 1-200, pref. 2-1:1-5. Ascorbic acid improves the digestive absorption of vincathione and hence the pharmaceutical activity.
VERAMYST Nasal Spray, 27.5 mcg per spray, is supplied in a brown glass bottle enclosed in a nasal device with a nozzle and a mist-release button to actuate the spray in a box of 1 (NDC 54868-6168-0) with FDA-Approved Patient Labeling (see Patient Instructions for Use for proper actuation of the device).   


Each bottle contains a net fill weight of 10 g of white, liquid suspension and will provide 120 metered sprays. After priming [see Dosage and Administration (2)], each spray delivers a fine mist containing 27.5 mcg of fluticasone furoate in 50 microliters of formulation through the nozzle. The contents of the bottle can be viewed through an indicator window. Shake the contents well before each use. The correct amount of medication in each spray cannot be assured before the initial priming and after 120 sprays have been used, even though the bottle is not completely empty. The nasal device should be discarded after 120 sprays have been used. 

Store the device in the upright position with the cap in place between 15° and 30°C (59° and 86°F). Do not freeze or refrigerate.
This phase II trial is studying how well giving nimotuzumab together with radiation therapy and cisplatin works in treating patients with previously untreated locally advanced cervical cancer. Monoclonal antibodies, such as nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that is approved in many countries for the treatment of EGFR-positive cancers. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Nimotuzumab also stop the growth of cervical cancer by increasing the effect of chemotherapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving nimotuzumab together with radiation therapy and cisplatin may kill more tumor cells.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely ophthalmology, and can be used in conducting anesthetic aids for laser vision correction in childhood. To do this, combined general anesthesia is performed using a laryngeal mask. Induction into anesthesia is carried out by a combination of inhalation of sevoflurane with a bolus load of 6 vol. %, followed by the administration of propofol at a dose of 3 mg/kg of weight intravenously (IV). Analgesia is achieved by the introduction of fentanyl at a dose of 2 mcg/kg of weight IV and the use of a local anesthetic, oxybuprocaine hydrochloride, which is instilled into the conjunctival sac, 1 drop before and after surgery. In premedication, for better recognition of the pupil with a laser, atropine is used at a dose of 0.01 mg/kg of weight, IV. Artificial ventilation of the lungs, controlled in Volume Control mode (respiratory volume: 6 ml/kg), is carried out with the possibility of triggering inspiration. Anesthesia is maintained by inhalation anesthesia with sevorane at the rate of 1.2 MAC, with a minimum alveolar concentration. To achieve the optimal position of the eye, the muscle relaxant atracuria bezilate is used at a dose of 0.1 mg/kg of weight without depression of the respiratory muscles.EFFECT: method provides adequate anesthesia during laser vision correction in this category of patients, which causes the creation of an even eye position in the central area of the cornea under general anesthesia without manual control by the surgeon, while significantly reducing the likelihood of postoperative complications in the form of postoperative astigmatism.1 cl, 1 ex
Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to golimumab in the trials described below with the incidence of antibodies in other trials or to other products may be misleading.

Using an enzyme immunoassay (EIA) method, antibodies to golimumab were detected in 13 (3%) golimumab-treated patients following IV administration of SIMPONI ARIA in combination with MTX through Week 24 of Trial RA, of which all were neutralizing antibodies.

A drug-tolerant enzyme immunoassay (drug-tolerant EIA) method for detecting antibodies to golimumab was developed and validated. This method is approximately 16-fold more sensitive than the original EIA method with less interference from golimumab in serum. Through approximately 6 months, the incidence of antibodies to golimumab with the drug-tolerant EIA method for Trials RA, PsA, AS, and pJIA was 21%, 19%, 19% and 31%, respectively. Where tested, approximately one-third to one-half were neutralizing.

Patients with RA, PsA, AS and pJIA who developed antibodies to golimumab generally had lower trough steady-state serum concentrations of golimumab [see Clinical Pharmacology (12.3)].
Aspects of the disclosure relate to hair treatment compositions including about 0.1 to about 10 wt. % of a cationic surfactant; about 0.1 to about 10 wt. % of a fatty acid having a carbon chain of 12 or more carbons; about 0.1 to about 20 wt. % of a fatty alcohol; and about 50 wt. % or more of water, wherein all weight percentages are based on the total weight of the hair treatment composition. Additionally, the hair treatment compositions are formulated to have a molar ratio of the total amount of cationic surfactant to the total amount of fatty acid is about 1:0.8 to about 1:3 and a pH of about 2.5 to about 5.5. The disclosure also relates to methods for applying such hair treatment compositions.
BACKGROUND: Cerebrospinal fluid (CSF) leak during endoscopic endonasal transsphenoidal surgery can lead to postoperative complications. The clinical and anatomic risk factors of intraoperative CSF leak are not well defined. We applied a two-dimensional (2D) convolutional neural network (CNN) machine learning model to identify risk factors from preoperative magnetic resonance imaging.
METHODS: All adults who underwent endoscopic endonasal transsphenoidal surgery at our institution from January 2007 to March 2023 who had accessible preoperative stereotactic magnetic resonance imaging were included. A retrospective classic statistical analysis was performed to identify demographic, clinical, and anatomic risk factors of intraoperative CSF leak. Stereotactic T2-weighted brain magnetic resonance imaging scans were used to train and test a 2D CNN model.
RESULTS: Of 220 included patients, 81 (36.8%) experienced intraoperative CSF leak. Among all preoperative variables, visual disturbance was the only statistically significant identified risk factor (P = 0.008). The trained 2D CNN model predicted CSF leak with 92% accuracy and area under receiver operating characteristic curve of 0.90 (sensitivity of 86% and specificity of 93%). Class activation mapping of this model revealed that anatomic regions of CSF flow were most important in predicting CSF leak.
CONCLUSIONS: Further review of the class activation mapping gradients revealed regions of the diaphragma sellae, clinoid processes, temporal horns, and optic nerves to have anatomic correlation to intraoperative CSF leak risk. Additionally, visual disturbances from anatomic compression of the optic chiasm were the only identified clinical risk factor. Our 2D CNN model can help a treating team to better anticipate and prepare for intraoperative CSF leak.
The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33℃ but restriction at 37-39℃. The LAIV can be used to protect a subject in need thereof, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza.
A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
A pharmaceutical product comprising one or more elastase inhibitors and one or more growth factors for simultaneous, separate or sequential use to promote wound healing. The elastase inhibitors and growth factors may be combined in a single composition or be present in separate compositions. Growth factors include EGF, PDGF, VEGF, FGF, TGF, IGF-1, tissue growth factor and keratinocyte growth factor. A particularly preferred elastase inhibitor is alpha-1-antitrypsin (AAT), but others include elafin, elastinil, secretory leukocyte proteinase inhibitor or alpha-1-macroglobin. The pharmaceutical product may be topically administered or provided in the form of a wound dressing. An example describes the protective/stabilising effect of AAT on PDGF which is said to synergistically promote wound healing.
The present invention relates to medicinal tea for treating dizziness, which can effectively solve the treatment problem of the dizziness. The medicinal tea comprises agrimony, radix isatidis, honeycomb and Chinese wolfberry, wherein the medicines are firstly mixed together. The weight of water is from 6 to 10 times more than that of the medicine, and the liquid medicine is decocted to 1/2 concentrated solution of the water filling quantity and is filled in a container. The present invention can be taken for many times per day as drinking tea and thus be called as the medicinal tea, and the daily dose is about 500 ml. The present invention has the advantages of scientific compatibility, simpleness, low cost, easy preparation and convenient drinking and can be drunk at any time. The present invention has good curative effect, has the specific curative effect on the dizziness, vertigo and dark vision caused by the AIDS and has extensive development prospect.
Elevated protein-bound toxins including p-cresol (pCS) and indoxyl sulfate (IDS) as well as middle-molecular toxins such as beta2-microglobulin (B2M) which could not be removed by hemodialysis (HD) are obviously correlated with high mortality. High-efficiency post-dilution online hemodiafiltration (OL-HDF) using high-flux dialyzer and requiring high blood flow rate (BF ≥400 mL/min) has been reported to enhance pCS, IDS, and B2M removal and improve patient survival. Unfortunately, the majority of patients could not reach that high BF because of vascular access issue. We innovated the OL-HDF modality for this limited BF situation by integrating the novel super high-flux membrane dialyzer (SHF; PES-17Dα, Nipro Corporation, Japan) into pre-dilution OL-HDF. This randomized crossover study was conducted to compare the uremic toxin removals between the new modality (limited BF OL-HDF with SHF) and the control (high-efficiency OL-HDF). The OL-HDF patients were randomized to undergo either new modality or control for 2 weeks before crossover to the other modality for another 2 weeks. Removals of pCS and IDS as well as small and middle molecule toxins were compared. The pCS and IDS were measured by high performance liquid chromatography. The dialysate albumin loss and patient safety were also monitored.
How should I dispose of Oral Transmucosal Fentanyl Citrate (OTFC) after use?   


Partially used OTFC units may contain enough medicine to be harmful or fatal to a child or other adults who have not been prescribed OTFC. You must properly dispose of the OTFC handle right away after use even if there is little or no medicine left on it. Please follow these directions to dispose of the handle:

  1. Once you have finished the OTFC unit and the medicine is totally gone, throw the handle away in a place that is out of the reach of children.
  2. If any medicine remains on the handle after you have finished, place the handle under hot running water until the medicine is gone, and then throw the handle away out of the reach of children and pets.

  3. If you did not finish the entire OTFC unit and you cannot dissolve the medicine under hot running water right away, put the OTFC in the temporary storage bottle that you received in the OTFC Child Safety Kit for safe keeping. Push the OTFC unit into the opening on the top until it falls completely into the bottle. Never leave unused or partially used OTFC units where children or pets can get to them.
  4. Dispose of the handles in the temporary storage bottle as soon as you can by following the directions in steps 1 and 2. You must dispose of all handles in the temporary storage bottle at least once a day.



Do not flush entire unused OTFC units, OTFC handles, or blister packages down the toilet.
BACKGROUND: The fibrinogen-to-albumin ratio (FAR) has been identified as a new inflammatory marker for predicting the risk of cardiovascular diseases. Nevertheless, its prognostic relevance in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) remains uncertain.
METHODS: This study included a total of 1031 hospitalized patients diagnosed with MINOCA, enrolled consecutively. The primary outcome was the occurrence of major adverse cardiovascular events (MACE). Based on the median FAR value, patients were divided into high FAR (FARH) and low FAR (FAR-L) groups. Baseline clinical characteristics and the incidence of adverse events during the follow-up period were compared between the two groups. Various statistical methods were applied, including restricted cubic spline modeling, Kaplan-Meier survival analysis, and Cox proportional hazards modeling.
RESULTS: The median follow-up duration was 42.3 months, during which 157 patients (15.2 %) experienced MACE. The FAR-H group had a significantly higher incidence of MACE compared to the FAR-L group (21.2 % vs. 9.3 %, p < 0.001). Multivariate Cox regression analysis revealed that a higher FAR was an independent predictor of long-term MACE in MINOCA patients (hazard ratio = 2.76, 95 % confidence interval: 1.95-3.89, p < 0.001), after adjusting for relevant clinical variables.
CONCLUSIONS: An elevated FAR is linked to a poor long-term prognosis in patients with MINOCA.